Drug Database
Back to search

Iceland· IS-EU/1/07/405/011-020&031-040

Rasilez

A aliskiren product containing aliskirenum inn hemifúmarat, registered in Iceland by Noden Pharma DAC. The same ATC class is registered in 13 of our 19 countries.

ATC C09XA02

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedRasilezATCC09XA02REGISTER NO.IS-EU/1/07/405/011-02…PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about aliskirenum inn hemifúmaratAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Aliskiren is registered in 13 of 19 countries.

Countries holding a registration under ATC C09XA02 (aliskiren), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 9 of them publish a price we can compare per daily dose
Search aliskiren products by name

Aliskiren · ATC C09XA02

13 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of aliskiren costs, country by country.

Normalised to the WHO defined daily dose (0.15 g), the median price runs from $0.95 in Italy to $3.43 in United States — a ×3.6 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail
Open the full comparison — free accountDrug prices for market access

Aliskiren · price per daily dose (0.15 g)

USD · FX 28 Sept 2026

  • US United States$3.43 (acquisition cost)
  • IT Italy$0.95
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Aliskirenum INN hemifúmarat
Manufacturer
Noden Pharma DAC
Country
Iceland (IS)
ATC code
C09XA02
ATC class
Aliskiren
Defined daily dose
0.15 g, O
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 1

1 priced
  • ean
    973926
    98 stk x1 pakki
    ISK 36643

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

227 interactions on record for aliskiren.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check aliskiren against other medicinesHow interaction checks work

Aliskiren · interactions on record

227 records

  • 1 severe
  • 147 moderate
  • 26 info

Most severe, free to view

  • CiclosporinL04AD01severe
  • ClotrimazoleA01AB18moderate
  • AprepitantA04AD12moderate
  • RolapitantA04AD14moderate

53 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Aliskiren in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All aliskiren products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Liechtenstein · Rasilez
  • Norway · Rasilez

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/dab66502-2c3b-4348-a4ef-e9e003b9f51b
GET /v1/drugs/dab66502-2c3b-4348-a4ef-e9e003b9f51b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmuhúðuð tafla",
  "source": "lyfjastofnun",
  "atc_raw": "C09XA02",
  "marketed": false,
  "strength": "300 mg",
  "ma_number": "EU/1/07/405/011-020&031-040",
  "substance": "Aliskirenum INN hemifúmarat",
  "other_info": null,
  "legal_status": "(R) Lyfseðilsskylt",
  "ma_issued_serial": "39331"
}
API referenceMCP serverPlans

See everything about aliskiren.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console